Burney Co. Reduces Stake in Cencora, Inc. $COR

Burney Co. lowered its stake in Cencora, Inc. (NYSE:COR) by 26.0% in the 1st quarter, Holdings Channel reports. The firm owned 65,350 shares of the company’s stock after selling 22,933 shares during the quarter. Cencora accounts for approximately 0.6% of Burney Co.’s portfolio, making the stock its 23rd largest position. Burney Co.’s holdings in Cencora were worth $20,529,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the stock. Kemnay Advisory Services Inc. bought a new position in shares of Cencora in the fourth quarter valued at approximately $25,000. Oakworth Capital Inc. bought a new stake in Cencora during the 4th quarter worth approximately $26,000. Elyxium Wealth LLC bought a new stake in Cencora during the 4th quarter worth approximately $27,000. Archer Investment Corp lifted its stake in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares in the last quarter. Finally, Motiv8 Investments LLC purchased a new stake in Cencora in the 4th quarter worth approximately $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.8%

Shares of NYSE:COR opened at $298.80 on Tuesday. The stock has a market capitalization of $58.13 billion, a P/E ratio of 22.91, a price-to-earnings-growth ratio of 1.65 and a beta of 0.58. The stock’s 50-day moving average price is $277.66 and its 200-day moving average price is $319.86. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a net margin of 0.78% and a return on equity of 135.20%. The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period last year, the firm posted $4.42 EPS. The company’s revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, June 1st. Stockholders of record on Friday, May 15th were issued a $0.60 dividend. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.8%. Cencora’s dividend payout ratio (DPR) is currently 18.40%.

Cencora declared that its Board of Directors has approved a stock repurchase plan on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s management believes its stock is undervalued.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. Wells Fargo & Company reduced their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a research report on Monday, May 11th. William Blair assumed coverage on Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating on the stock. UBS Group lifted their price objective on Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Evercore set a $360.00 target price on Cencora in a research note on Wednesday, April 8th. Finally, Robert W. Baird lowered their price target on Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Eleven research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $367.75.

Insider Activity

In other news, Director Lauren M. Tyler bought 550 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $270.23 per share, with a total value of $148,626.50. Following the completion of the purchase, the director directly owned 4,359 shares in the company, valued at $1,177,932.57. This represents a 14.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 0.38% of the company’s stock.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.